Piper Sandler Maintains a Buy Rating on Cytokinetics (CYTK) With a $107 PT - Yahoo Finance
4 weeks ago • Google News
Cytokinetics Inc (CYTK)
US$ 30.485-2.63%
Price Chart
Key Statistics
Market Cap
$ 4.5B
P/E Ratio
0.00
Revenue (TTM)
$ 19.22M
Volume
1.26M
52W High
$ 59.39
52W Low
$ 29.31
Dividend Yield
0.00%
Beta
0.59
Technicals
50-Day MA
34.2514
200-Day MA
43.041
52 Week High
59.39
52 Week Low
29.31
About CYTK
Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating di.
Employees
498
Headquarters
South San Francisco, CA
CEO
Mr. Robert I. Blum
Latest News
Cytokinetics Merits A Speculative Buy Rating (NASDAQ:CYTK) - Seeking Alpha
1 weeks ago • Google News
Cytokinetics to Present New Aficamten Data at ESC Congress 2025 - Insider Monkey
Yesterday • Google News
Top Gainers
Symbol/Name
LTP
% Chg
Top Losers
Symbol/Name
LTP
% Chg